Binding and inhibition of drug transport proteins by heparin

References

• Wind NS, Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer 2011; 2011:967419; http://dx.doi.org/10.4061/2011/967419; PMID: 22332018
   PubMedGoogle Scholar
• Petzinger E, Geyer J. Drug transporters in pharmacokinetics. Naunyn Schmiedebergs Arch Pharmacol 2006; 372:465 - 75; http://dx.doi.org/10.1007/s00210-006-0042-9; PMID: 16532306
   PubMed Web of Science ®Google Scholar
• Jäeger W. Classical resistance mechanisms. Int J Clin Pharmacol Ther 2009; 47:46 - 8; http://dx.doi.org/10.5414/CPP47046; PMID: 19203536
   PubMed Web of Science ®Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9:105 - 27; http://dx.doi.org/10.2217/14622416.9.1.105; PMID: 18154452
   PubMed Web of Science ®Google Scholar
• Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58:931 - 59; http://dx.doi.org/10.1007/PL00000912; PMID: 11497241
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116:5377 - 82; http://dx.doi.org/10.1182/blood-2010-02-270116; PMID: 20829374
   PubMed Web of Science ®Google Scholar
• Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program 2010; 2010:144 - 9; http://dx.doi.org/10.1182/asheducation-2010.1.144; PMID: 21239784
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22:1944 - 8; http://dx.doi.org/10.1200/JCO.2004.10.002; PMID: 15143088
   PubMed Web of Science ®Google Scholar
• Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23:2130 - 5; http://dx.doi.org/10.1200/JCO.2005.03.134; PMID: 15699479
   PubMed Web of Science ®Google Scholar
• Cunningham MS, Preston RJ, O’Donnell JS. Does antithrombotic therapy improve survival in cancer patients?. Blood Rev 2009; 23:129 - 35; http://dx.doi.org/10.1016/j.blre.2008.10.002; PMID: 19046797
   PubMed Web of Science ®Google Scholar
• von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol 2000; 16:815 - 24; PMID: 10717252
   PubMed Web of Science ®Google Scholar
• Chen Y, Scully M, Dawson G, Goodwin C, Xia M, Lu X, Kakkar A. Perturbation of the heparin/heparin-sulfate interactome of human breast cancer cells modulates pro-tumourigenic effects associated with PI3K/Akt and MAPK/ERK signalling. Thromb Haemost 2013; 109:1148 - 57; http://dx.doi.org/10.1160/TH12-12-0935; PMID: 23571852
   PubMed Web of Science ®Google Scholar
• Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004; 1:27 - 42; http://dx.doi.org/10.2174/1567201043480036; PMID: 16305368
   PubMedGoogle Scholar
• Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22:7340 - 58; http://dx.doi.org/10.1038/sj.onc.1206938; PMID: 14576842
   PubMed Web of Science ®Google Scholar
• Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 2010; 11:603 - 17; http://dx.doi.org/10.2174/138920010792927325; PMID: 20812902
   PubMed Web of Science ®Google Scholar
• Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205:275 - 92; http://dx.doi.org/10.1002/path.1706; PMID: 15641020
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92:1295 - 302; http://dx.doi.org/10.1093/jnci/92.16.1295; PMID: 10944550
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang J, Zhang L, Zhao L, Fan S, Yang Z, Gao F, Kong Y, Xiao GG, Wang Q. Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell lines. Oncol Rep 2011; 26:1081 - 9; PMID: 21805041
   PubMed Web of Science ®Google Scholar
• Ikeda K, Oka M, Yamada Y, Soda H, Fukuda M, Kinoshita A, Tsukamoto K, Noguchi Y, Isomoto H, Takeshima F, et al. Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes. Int J Cancer 1999; 82:599 - 604; http://dx.doi.org/10.1002/(SICI)1097-0215(19990812)82:4<599::AID-IJC21>3.0.CO;2-R; PMID: 10404077
   PubMed Web of Science ®Google Scholar
• Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P, Scheper RJ. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996; 148:877 - 87; PMID: 8774142
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995; 1:578 - 82; http://dx.doi.org/10.1038/nm0695-578; PMID: 7585126
   PubMed Web of Science ®Google Scholar
• Bontenbal M, Sonneveld P, Foekens JA, Klijn JG. Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7). Eur J Cancer Clin Oncol 1988; 24:1409 - 14; http://dx.doi.org/10.1016/0277-5379(88)90329-X; PMID: 3181264
   PubMedGoogle Scholar
• Ang EZ, Nguyen HT, Sim HL, Putti TC, Lim LH. Annexin-1 regulates growth arrest induced by high levels of estrogen in MCF-7 breast cancer cells. Mol Cancer Res 2009; 7:266 - 74; http://dx.doi.org/10.1158/1541-7786.MCR-08-0147; PMID: 19208747
   PubMed Web of Science ®Google Scholar
• Langlois B, Perrot G, Schneider C, Henriet P, Emonard H, Martiny L, Dedieu S. LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One 2010; 5:e11584; http://dx.doi.org/10.1371/journal.pone.0011584; PMID: 20644732
   PubMed Web of Science ®Google Scholar
• Geetha N, Mihaly J, Stockenhuber A, Blasi F, Uhrin P, Binder BR, Freissmuth M, Breuss JM. Signal integration and coincidence detection in the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) cascade: concomitant activation of receptor tyrosine kinases and of LRP-1 leads to sustained ERK phosphorylation via down-regulation of dual specificity phosphatases (DUSP1 and -6). J Biol Chem 2011; 286:25663 - 74; http://dx.doi.org/10.1074/jbc.M111.221903; PMID: 21610072
   PubMed Web of Science ®Google Scholar
• Steiner E, Holzmann K, Elbling L, Micksche M, Berger W. Cellular functions of vaults and their involvement in multidrug resistance. Curr Drug Targets 2006; 7:923 - 34; http://dx.doi.org/10.2174/138945006778019345; PMID: 16918321
   PubMed Web of Science ®Google Scholar
• Angelini A, Ciofani G, Baccante G, Di Febbo C, Carmine DI, Cuccurullo F, Porreca E. Modulatory effects of heparin on cellular accumulation and cytotoxicity of doxorubicin in MRP1-overexpressing HL60/doxo cells. Anticancer Res 2007; 27:1A 351 - 5; PMID: 17352253
   PubMedGoogle Scholar
• Angelini A, Di Febbo C, Ciofani G, Di Nisio M, Baccante G, Di Ilio C, Cuccurullo F, Porreca E. Inhibition of P-glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy. Cancer Biol Ther 2005; 4:313 - 7; http://dx.doi.org/10.4161/cbt.4.3.1503; PMID: 15876859
   PubMed Web of Science ®Google Scholar
• Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM, Georges E. Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun 2004; 314:565 - 70; http://dx.doi.org/10.1016/j.bbrc.2003.12.117; PMID: 14733945
   PubMed Web of Science ®Google Scholar
• Ori A, Wilkinson MC, Fernig DG. A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J Biol Chem 2011; 286:19892 - 904; http://dx.doi.org/10.1074/jbc.M111.228114; PMID: 21454685
   PubMed Web of Science ®Google Scholar
• Redwood C, Davies SL, Wells NJ, Fry AM, Hickson ID. Casein kinase II stabilizes the activity of human topoisomerase IIalpha in a phosphorylation-independent manner. J Biol Chem 1998; 273:3635 - 42; http://dx.doi.org/10.1074/jbc.273.6.3635; PMID: 9452492
   PubMed Web of Science ®Google Scholar
• Rusnati M, Urbinati C, Caputo A, Possati L, Lortat-Jacob H, Giacca M, Ribatti D, Presta M. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 2001; 276:22420 - 5; http://dx.doi.org/10.1074/jbc.M010779200; PMID: 11304529
   PubMed Web of Science ®Google Scholar
• Zurita AJ, Diestra JE, Condom E, García Del Muro X, Scheffer GL, Scheper RJ, Pérez J, Germà-Lluch JR, Izquierdo MA. Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br J Cancer 2003; 88:879 - 86; http://dx.doi.org/10.1038/sj.bjc.6600803; PMID: 12644825
   PubMed Web of Science ®Google Scholar
• Huffman KE, Corey DR. Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line. Biochemistry 2005; 44:2253 - 61; http://dx.doi.org/10.1021/bi047948g; PMID: 15709737
   PubMed Web of Science ®Google Scholar
• van Zon A, Mossink MH, Schoester M, Scheper RJ, Sonneveld P, Wiemer EA. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression. Cancer Res 2004; 64:4887 - 92; http://dx.doi.org/10.1158/0008-5472.CAN-03-3891; PMID: 15256459
   PubMed Web of Science ®Google Scholar
• Herlevsen M, Oxford G, Owens CR, Conaway M, Theodorescu D. Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Mol Cancer Ther 2007; 6:1804 - 13; http://dx.doi.org/10.1158/1535-7163.MCT-06-0372; PMID: 17575109
   PubMed Web of Science ®Google Scholar
• Han M, Lv Q, Tang XJ, Hu YL, Xu DH, Li FZ, Liang WQ, Gao JQ. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Control Release 2012; 163:136 - 44; http://dx.doi.org/10.1016/j.jconrel.2012.08.020; PMID: 22940126
   PubMed Web of Science ®Google Scholar
• Daoud R, Kast C, Gros P, Georges E. Rhodamine 123 binds to multiple sites in the multidrug resistance protein (MRP1). Biochemistry 2000; 39:15344 - 52; http://dx.doi.org/10.1021/bi0020574; PMID: 11112520
   PubMed Web of Science ®Google Scholar
• Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, Bates SE. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004; 64:1242 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-03-3298; PMID: 14973080
   PubMed Web of Science ®Google Scholar
• Wesołowska O. Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1. Acta Biochim Pol 2011; 58:433 - 48; PMID: 22187677
   PubMed Web of Science ®Google Scholar
• Chu TS, Chen JS, Lopez JP, Pardo FS, Aguilera J, Ongkeko WM. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2008; 134:979 - 84; http://dx.doi.org/10.1001/archotol.134.9.979; PMID: 18794444
   PubMed Web of Science ®Google Scholar
• An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells?. Expert Opin Drug Metab Toxicol 2009; 5:1529 - 42; http://dx.doi.org/10.1517/17425250903228834; PMID: 19708828
   PubMed Web of Science ®Google Scholar
• Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, et al. Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005; 167:1699 - 711; http://dx.doi.org/10.1016/S0002-9440(10)61252-7; PMID: 16314481
   PubMed Web of Science ®Google Scholar